Comparing biologic treatments for inflammatory bowel disease
Part of Digestive system clinical trials.
This study looks at how well different biologic medications work for people with moderate to severe ulcerative colitis or Crohn's disease after one year of treatment. The goal is to see which treatment helps the gut heal best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe ulcerative colitis or Crohn's disease.
- You are starting a biologic medicine like adalimumab, infliximab, ustekinumab, or vedolizumab for the first time.
- You have been on this medicine for at least 6 weeks but no more than 12 months.
- You have not taken any other biologic medicines before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares four newer biologic medications (infliximab, filgotinib, vedolizumab, and ustekinumab) to find which works best as a first biologic treatment for ulcerative colitis that hasn't responded well to standard drugs. It aims to help doctors choose the right biologic for each patient.
This study looks at why some people with inflammatory bowel disease (Crohn's or ulcerative colitis) do not respond to certain biologic treatments. Researchers will use advanced testing (multi-omics) to better understand treatment response. If you are starting or have just started treatment with infliximab, adalimumab, vedolizumab, or ustekinumab, you may be able to join.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
Hear when a new Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.